Pfizer and Medivation to Co-Develop and Market Alzheimer’s and Huntington’s Treatment
Pfizer Inc. (New York, NY) and Medivation, Inc. (San Francisco, CA) have joined forces to develop and commercialize Dimebon, Medivation’s investigational drug for treating Alzheimer’s disease and Huntington’s disease.
Pfizer Inc. (New York, NY) and Medivation, Inc. (San Francisco, CA) have joined forces to develop and commercialize Dimebon, Medivation’s investigational drug for treating Alzheimer’s disease and Huntington’s disease. Dimebon is currently being evaluated in an international, confirmatory Phase 3 trial in patients with mild-to-moderate Alzheimer’s disease (www.connectionstudy.com).
Under the terms of the agreement, Medivation will receive an up front cash payment of $225 million. Medivation and Pfizer will collaborate on the Phase 3 program in Alzheimer’s disease, Huntington’s disease, and regulatory filings in the United States. The companies will share all US development and commercialization expenses along with US profits/losses on a 60/40% basis, with Pfizer assuming the larger share of both expenses and profit/losses. In addition, Medivation will co-promote Dimebon to specialty physicians in the US.
Pfizer will have the responsibility for development, regulatory, and commercialization outside the US and will pay Medivation tiered royalties on commercial sales outside of the US.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
